The global Acute Bacterial Skin and Skin Structure Infections Market is estimated to be valued at US$ 3,466.6 Mn in 2023 and is expected to exhibit a CAGR of 6.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Acute bacterial skin and skin structure infections, also known as ABSSSIs, refer to bacterial infections of the deeper skin structures and subcutaneous tissues that require antibiotic treatment. The market has seen significant growth due to rising prevalence of skin infections associated with surgical procedures along with increasing healthcare expenditure worldwide.
Market key trends:
Growth Accelerated by Innovative Treatment Options: The Acute Bacterial Skin and Skin Structure Infections market is driven by a surge in demand for innovative treatment options. There has been an increased focus on research and development of novel drugs to treat antibiotic-resistant bacterial strains. This has led to approval and launch of new drugs such as ceftobiprole, plazomicin and eravacycline which target multi-drug resistant pathogens. Their superiority over conventional antibiotic therapies in terms of enhanced efficacy, reduced treatment duration and improved safety profiles is expected to boost their uptake. Expanding indication approval for established drugs to cover ABSSSI is another key strategy adopted by manufacturers to accelerate growth in the lucrative market.
Segment Analysis
The global acute bacterial skin and skin structure infections market can be segmented based on condition, treatment, route of administration, distribution channel, and geography. Based on condition, the market is segmented into impetigo, cellulitis, cutaneous abscess, and others. The cutaneous abscess segment dominates the market owing to easy availability of treatment and rising cases of skin infections.
Key Takeaways
The global acute bacterial skin and skin structure infections market is expected to witness high growth.
Regional analysis: North America is expected to be the fastest growing region in the global acute bacterial skin and skin structure infections market during the forecast period. This is attributed to increasing incidences of skin infections and presence of key players in the region.
Key players: Key players operating in the acute bacterial skin and skin structure infections market are Fresenius SE & Co. KGaA, Pfizer, Inc., Amneal Pharmaceuticals LLC, Intas Pharmaceuticals Ltd., Cadila Healthcare Ltd., Glenmark Pharmaceuticals Ltd, GlaxoSmithKline plc., Sun Pharmaceutical Industries Ltd., Sandoz Inc., Aurobindo Pharma Ltd., AbbVie, Inc., Melinta Therapeutics, Inc., Accord Healthcare Ltd., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., and Paratek Pharmaceuticals, Inc.
No comments:
Post a Comment